Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estudio de ALV-100 para evaluar la seguridad, tolerabilidad y PK/PD en participantes con sobrepeso/obesidad con o sin T2D

15 de octubre de 2026 actualizado por: Alveus Therapeutics, Inc.

Un estudio de Fase 1b, aleatorizado, doble ciego, controlado con placebo y de escalada de dosis que evalúa la seguridad, tolerabilidad, farmacocinética y farmacodinámica de ALV-100 en participantes con sobrepeso u obesidad con o sin diabetes tipo 2

A Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants with or without Type 2 Diabetes

Descripción general del estudio

Estado

Activo, no reclutando

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

180

Fase

  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Florida
      • Miami, Florida, Estados Unidos, 33172
        • Clinical Pharmacology of Miami
    • Ohio
      • Columbus, Ohio, Estados Unidos, 43212
        • Ohio Clinical Trials
    • Texas
      • San Antonio, Texas, Estados Unidos, 78240
        • Endeavor Clinical Trials

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 65 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

For Part A and B

  • Adult male and female participants, aged 18 to 65 years, inclusive, at the time of signing the informed consent form
  • Body mass index between 27.0 to 39.9 kg/m2 at Screening, both inclusive; overweight should be due to excess adipose tissue, as judged by the Investigator.
  • Have a stable body weight (< 5.0 kg/11 lbs self-reported change) within 90 days prior to Screening
  • Females must be surgically sterile (by means of bilateral salpingectomy, hysterectomy or bilateral oophorectomy) or be post-menopausal (defined as spontaneous cessation of menses for at least 1 year prior to Screening). Females who are post-menopausal and < 55 years must have a follicle-stimulating hormone level > 40 IU/L at Screening.
  • Males with female partners of child-bearing potential must be willing to practice abstinence or must agree to use condom as contraception throughout the duration of the study. This criterion may be waived for male participants who have had a documented successful vasectomy > 6 months before signing the ICF.

For Part B only

  • Diagnosis of Type 2 Diabetes for at least 180 days prior to Screening.
  • Glycemic control managed by diet and exercise alone or by stable treatment with metformin and/or sodium-glucose cotransporter 2 inhibitors (SGLT-2i), with no dose changes within 3 months prior to Screening.
  • Hemoglobin A1c (HbA1c) between 6.5 % and 9.0% (equivalent to 48-75 mmol/mol), both inclusive, at Screening.

Exclusion Criteria:

For Part A and B

  • History or presence of any clinically relevant respiratory, metabolic (including dyslipidemia, however screening total cholesterol below or equal to 302 mg/dL (7.8 mmol/L) and/or screening triglyceride below or equal to 500 mg/dL (5.65 mmol/L) is accepted), renal, hepatic, gastrointestinal, endocrinological conditions (except conditions associated with type 2 diabetes in Part B) at the discretion of the Investigator.
  • Participants with a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 or a personal history of nonfamilial medullary thyroid carcinoma.
  • Current or history of chronic or acute pancreatitis.
  • Obesity caused by known endocrinologic disorders (e.g., Cushing syndrome) or monogenetic or syndromic forms of obesity (for example, Melanocortin 4 Receptor deficiency or Prader Willi Syndrome).
  • History of major depressive disorder or other severe psychiatric disorder (for example, schizophrenia, bipolar disorder, or anxiety disorder).
  • Lifetime history of a suicide attempt or of any suicidal behavior by endorsement of (answered yes to) any of the items in the suicidal behavior section on the Columbia Suicide Severity Rating Scale (C-SSRS) at Screening.
  • Systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg at Screening.
  • History of or current cardiovascular disease, including but not limited to stable and unstable angina, myocardial infarction, congestive heart failure, transient ischemic attack, stroke, clinically significant arrhythmias and conduction disorders or venous thromboembolism.

Part A only

• History or clinical evidence of Type 1 or Type 2 diabetes mellitus, including HbA1c ≥ 6.5% and/or a fasting plasma glucose (FPG) ≥ 126 mg/dL (7.0 mmol/L) at Screening (female participants with a history of gestational diabetes are allowed).

Part B only

  • Fasting plasma glucose (FPG) > 270 mg/dL (15.0 mmol/L) at Screening.
  • Proliferative retinopathy or maculopathy as judged by the investigator based on a recent (within1.5 years from Screening) ophthalmologic examination.
  • Severe neuropathy as judged by the investigator.
  • Advanced nephropathy (defined as albuminuria ≥ 300 mg/g).
  • History of severe hypoglycemia or hypoglycemic unawareness as judged by the investigator.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación Secuencial
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Part A - Cohort 1 (ALV-100)

Participants with overweight or obesity without type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection.

Participants will receive multiple ascending doses of ALV-100.

Comparador de placebos: Part A - Cohort 1 (Placebo)

Participants with overweight or obesity without type 2 diabetes will receive placebo by subcutaneous injection.

Participants will receive placebo matching ALV-100, volume-matched to active dose.

Experimental: Part A - Cohort 2 (ALV-100)

Participants with overweight or obesity without type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection.

Participants will receive multiple ascending doses of ALV-100.

Comparador de placebos: Part A - Cohort 2 (Placebo)

Participants with overweight or obesity without type 2 diabetes will receive placebo by subcutaneous injection.

Participants will receive placebo matching ALV-100, volume-matched to active dose.

Experimental: Part A - Cohort 3 (ALV-100)

Participants with overweight or obesity without type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection.

Participants will receive multiple ascending doses of ALV-100.

Comparador de placebos: Part A - Cohort 3 (Placebo)

Participants with overweight or obesity without type 2 diabetes will receive placebo by subcutaneous injection.

Participants will receive placebo matching ALV-100, volume-matched to active dose.

Experimental: Part A - Cohort 4 (ALV-100)

Participants with overweight or obesity without type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection.

Participants will receive multiple ascending doses of ALV-100.

Comparador de placebos: Part A - Cohort 4 (Placebo)

Participants with overweight or obesity without type 2 diabetes will receive placebo by subcutaneous injection.

Participants will receive placebo matching ALV-100, volume-matched to active dose.

Experimental: Part B - T2D Cohort (ALV-100)

Participants with overweight or obesity with type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection.

Participants will receive multiple ascending doses of ALV-100.

Comparador de placebos: Part B - T2D Cohort (Placebo)

Participants with overweight or obesity with type 2 diabetes will receive placebo by subcutaneous injection.

Participants will receive placebo matching ALV-100, volume-matched to active dose.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Safety and tolerability
Periodo de tiempo: From First Dose to Week 52

Incidence of treatment emergent adverse events (TEAEs)

From First Dose to Week 52

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Pharmacokinetics (PK) of intact ALV-100 and total ALV-100 - Cmax, MD
Periodo de tiempo: From First Dose to Week 52

Maximum observed serum concentration after multiple doses (MD) (Cmax, MD)

From First Dose to Week 52
Pharmacokinetics (PK) of intact ALV-100 and total ALV-100 - AUC(0-τ), MD
Periodo de tiempo: From First Dose to Week 52

Area under the serum concentration-time curve from time zero to τ, where τ is the dosing interval, (AUC(0-τ), MD)

From First Dose to Week 52
Pharmacodynamic (PD) impact on body weight
Periodo de tiempo: Baseline, Week 32 and Week 52

Change from baseline in body weight

Baseline, Week 32 and Week 52
Pharmacodynamic (PD) impact on body weight percentage
Periodo de tiempo: Baseline, Week 32 and Week 52

Change from baseline in body weight percentage

Baseline, Week 32 and Week 52
Immunogenicity
Periodo de tiempo: From Baseline to Week 52

Incidence of Anti-ALV-100 drug antibodies, including assessments of cross-reactivity and neutralizing antibodies.

From Baseline to Week 52
Relationship between ALV-100 serum concentration and QTc interval changes (Part A Only)
Periodo de tiempo: From First Dose to Week 52

Measurement of change in individual specific heart rate corrected QT interval (QTcI) and Fridericia heart rate corrected QT interval (QTcF) on 12-lead ECG.

From First Dose to Week 52
Paracetamol (acetaminophen) absorption test (PAT) (Part A Only)
Periodo de tiempo: From First Dose to Week 52

Measurement of acetaminophen PK parameters to evaluate the effect of ALV-100 on the gastric emptying rate.

From First Dose to Week 52
Pharmacodynamic (PD) impact of ALV-100 on antidiabetic medication (Part B Only)
Periodo de tiempo: From Baseline to Week 32

Change in use of concomitant glucose-lowering medication

From Baseline to Week 32
Pharmacodynamic (PD) impact of ALV-100 on glycemic parameters (Part B Only)
Periodo de tiempo: Week 32 and Week 52

Measuring the number of participants achieving target Hemoglobin A1c values

Week 32 and Week 52
Hypoglycemic Safety (Part B Only)
Periodo de tiempo: From Baseline to Week 52

Measured by the incidence of symptomatic hypoglycemia, documented symptomatic hypoglycemia and severe hypoglycemia

From Baseline to Week 52

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Director de estudio: Karen Tornøe, MD, PhD, Alveus Therapeutics

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

29 de diciembre de 2025

Finalización primaria (Estimado)

1 de octubre de 2027

Finalización del estudio (Estimado)

1 de octubre de 2027

Fechas de registro del estudio

Enviado por primera vez

15 de enero de 2026

Primero enviado que cumplió con los criterios de control de calidad

3 de febrero de 2026

Publicado por primera vez (Actual)

10 de febrero de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

16 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

15 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir